ArticleCirculation2022
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction.ESC heart failure · 2026Pooled it
- European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure.European journal of heart failure · 2025Guideline
- Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.ESC heart failure · 2024Pooled it
- Cardiac biomarkers response under angiotensin receptor-neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study.ESC heart failure · 2026Trial
- Trial
- Reverse Remodeling Following Sacubitril/Valsartan Initiation in CRT-Treated HFrEF Patients: Insights from a Real-World Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of RAS inhibitors on 2-year mortality and disease progression in chronic mitral regurgitation.BMC cardiovascular disorders · 2026Article
- Factors associated with the development of severe mitral regurgitation in patients with heart failure.Open heart · 2026Article
- Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.ESC heart failure · 2026Review
- Transcatheter mitral repair in patients with symptomatic moderate functional mitral regurgitation: 1-year outcomes from the MiCLASP study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-regurgitation study.European heart journal · 2025Article
- Functional Mitral Regurgitation and the Role of Transcatheter Repair.Structural heart : the journal of the Heart Team · 2025Review
- Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.ESC heart failure · 2025Review
- Outcome Improvement with Last-Generation Devices in Mitral Transcatheter Edge-to-Edge Repair: Insights from the Real-World MitraClip Florence Registry.Journal of clinical medicine · 2025Article
- 2024 update in heart failure.ESC heart failure · 2025Review
- Early sacubitril/valsartan use associated with reduced atrial fibrillation risk in patients with acute myocardial infarction complicated by mitral regurgitation: a retrospective cohort study.Frontiers in cardiovascular medicine · 2025Article
- COAPT Trial at 5 Years: Same Doubts Remain About the Efficacy of Transcatheter Edge-to-Edge in Functional Mitral Regurgitation.Brazilian journal of cardiovascular surgery · 2024Article
- Atrial Functional Mitral Regurgitation: From Diagnosis to Current Interventional Therapies.Journal of clinical medicine · 2024Review
- Management of secondary mitral regurgitation: from drugs to devices.Heart (British Cardiac Society) · 2024Review
- Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.